Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
Adolescent
Antineoplastic Agents, Immunological
/ therapeutic use
Burkitt Lymphoma
/ drug therapy
Child
Child, Preschool
Combined Modality Therapy
Female
Humans
Immunotherapy
/ methods
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Prospective Studies
Remission Induction
Republic of Belarus
Rituximab
/ therapeutic use
Russia
Treatment Outcome
chemotherapy
children
mature B-cell lymphoma
rituximab
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
23
11
2018
accepted:
12
02
2019
pubmed:
10
5
2019
medline:
23
5
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
The value of adding rituximab to chemotherapy in children with aggressive B-cell non-Hodgkin lymphoma (B-NHL) is still insufficiently studied. We enrolled 231 patients [mean age 9 years old (range 2-17); male:female ratio 3·4:1] with Burkitt (BL, 179 patients, 76·7%), diffuse large B-cell (32 patients, 14%), primary mediastinal B-cell (14 patients, 6%), and other (6 patients, 2·6%) B-cell lymphomas in a prospective study of immuno-chemotherapy. Stages were I-II in 32% and III-IV in 68% of the patients. Four doses of 375 mg/m
Substances chimiques
Antineoplastic Agents, Immunological
0
Rituximab
4F4X42SYQ6
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
477-483Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.